On Thursday, Keryx Biopharmaceuticals (NASDAQ:KERX)’s shares inclined 2.61% to $10.21.
Keryx Biopharmaceuticals, Inc., (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, recently declared that it will present at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 24, 2015 at 2:30 p.m. EDT.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s shares gained 3.12% to $8.93. Achillion Pharmaceuticals, Inc. (ACHN) declared that members of the senior administration team will present a corporate overview at the JMP Securities Life Sciences Conference on Tuesday, June 23, 2015 at 9:00 a.m. ET at The St. Regis New York Hotel in New York, NY.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
At the end of Thursday’s trade, Fiserv Inc (NASDAQ:FISV)‘s shares surged 2.18% to $82.69.
Fiserv, Inc. (FISV), a leading global provider of financial services technology solutions, has expanded its card production capabilities to comprise milling and embedding, enabling the company to complete the entire EMV™ chip card production process in house and streamline the migration to EMV chip cards for clients.
With state-of-the-art milling and embedding technology, Fiserv adds to its extensive EMV capabilities, counting card personalization, transaction processing, real-time payments and funds access through the Accel® debit payments network, risk administration, staff and consumer education support, and planned guidance.
Fiserv, Inc., together with its auxiliaries, provides financial services technology worldwide. The companys Payments and Industry Products segment provides debit, credit, and prepaid card processing and services; electronic bill payment and presentment services; Internet and mobile banking software and services; person-to-person payment services; and other electronic payments software and services.
Penn Virginia Corporation (NYSE:PVA), ended its Thursday’s trading session with -2.15% loss, and closed at $4.09.
Penn Virginia Corporation (PVA) which has witnessed a noteworthy price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in PVA.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 4 estimates moving down in the past 30 days, contrast with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $1.48 a share a month ago to its current level of a loss of $2.10.
Also, for the current quarter, Penn Virginia has seen 2 downward estimate revisions as compared to no revisions in the opposite direction, dragging the consensus estimate down to a loss of 51 cents a share from a loss of 32 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 21.9% in the past month.
Penn Virginia Corporation, an independent oil and gas company, explores, develops, and produces crude oil, natural gas liquids, and natural gas in various onshore regions of the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
